Kala Pharmaceuticals Stock Performance
| KALA Stock | USD 6.92 0.12 1.76% |
On a scale of 0 to 100, Kala Pharmaceuticals holds a performance score of 5. The company secures a Beta (Market Risk) of 1.35, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kala Pharmaceuticals will likely underperform. Please check Kala Pharmaceuticals' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether Kala Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Kala Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat conflicting essential indicators, Kala Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.76 | Five Day Return 5.65 | Year To Date Return (10.25) | Ten Year Return (99.25) | All Time Return (99.25) |
Last Split Factor 1:50 | Last Split Date 2022-10-21 |
1 | KALA BIO Announces 10,750,000 Private Placement | 12/30/2024 |
2 | Acquisition by Reumuth Mary of 45200 shares of Kala Pharmaceuticals at 7.53 subject to Rule 16b-3 | 01/06/2025 |
3 | Disposition of 7392 shares by Mark Iwicki of Kala Pharmaceuticals at 6.09 subject to Rule 16b-3 | 01/13/2025 |
4 | KALA stock soars to 52-week high, reaching 8.81 By Investing.com - Investing.com Nigeria | 01/28/2025 |
5 | KALA BIO Announces CEO Resignation and Appointment of Interim Chief Executive OfficerOn February 11, 2025, KALA BIO, Inc. revealed in an 8-K filing with the Sec... | 02/14/2025 |
6 | Acquisition by Reumuth Mary of 10100 shares of Kala Pharmaceuticals subject to Rule 16b-3 | 02/24/2025 |
7 | Disposition of 2093 shares by Todd Bazemore of Kala Pharmaceuticals at 6.09 subject to Rule 16b-3 | 02/27/2025 |
8 | Acquisition by Todd Bazemore of 45200 shares of Kala Pharmaceuticals at 7.05 subject to Rule 16b-3 | 03/07/2025 |
| Begin Period Cash Flow | 70.7 M |
Kala |
Kala Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 600.00 in Kala Pharmaceuticals on December 23, 2024 and sell it today you would earn a total of 92.00 from holding Kala Pharmaceuticals or generate 15.33% return on investment over 90 days. Kala Pharmaceuticals is currently generating 0.4588% in daily expected returns and assumes 6.4064% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Kala, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kala Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kala Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kala Pharmaceuticals, and traders can use it to determine the average amount a Kala Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0716
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | KALA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.41 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.46 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Kala Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kala Pharmaceuticals by adding it to a well-diversified portfolio.
Kala Pharmaceuticals Fundamentals Growth
Kala Stock prices reflect investors' perceptions of the future prospects and financial health of Kala Pharmaceuticals, and Kala Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kala Stock performance.
| Return On Equity | -4.31 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 29.99 M | ||||
| Shares Outstanding | 6.09 M | ||||
| Price To Earning | (0.52) X | ||||
| Price To Book | 6.15 X | ||||
| Price To Sales | 1.16 X | ||||
| Gross Profit | 1.33 M | ||||
| EBITDA | (36.08 M) | ||||
| Net Income | (42.2 M) | ||||
| Cash And Equivalents | 44.57 M | ||||
| Cash Per Share | 30.44 X | ||||
| Total Debt | 36.32 M | ||||
| Debt To Equity | 4.77 % | ||||
| Current Ratio | 2.54 X | ||||
| Book Value Per Share | 1.49 X | ||||
| Cash Flow From Operations | (27.93 M) | ||||
| Earnings Per Share | (11.67) X | ||||
| Market Capitalization | 42.15 M | ||||
| Total Asset | 55.95 M | ||||
| Retained Earnings | (629.41 M) | ||||
| Working Capital | 44.52 M | ||||
| Current Asset | 84.65 M | ||||
| Current Liabilities | 10.53 M | ||||
About Kala Pharmaceuticals Performance
By analyzing Kala Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Kala Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kala Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kala Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.3 K | 1.1 K | |
| Return On Tangible Assets | (0.68) | (0.71) | |
| Return On Capital Employed | (0.74) | (0.78) | |
| Return On Assets | (0.68) | (0.71) | |
| Return On Equity | (5.06) | (5.31) |
Things to note about Kala Pharmaceuticals performance evaluation
Checking the ongoing alerts about Kala Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kala Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kala Pharmaceuticals had very high historical volatility over the last 90 days | |
| Kala Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (42.2 M) with profit before overhead, payroll, taxes, and interest of 1.33 M. | |
| Kala Pharmaceuticals currently holds about 44.57 M in cash with (27.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 30.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Kala Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Todd Bazemore of 45200 shares of Kala Pharmaceuticals at 7.05 subject to Rule 16b-3 |
- Analyzing Kala Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kala Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Kala Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kala Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kala Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kala Pharmaceuticals' stock. These opinions can provide insight into Kala Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kala Stock analysis
When running Kala Pharmaceuticals' price analysis, check to measure Kala Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kala Pharmaceuticals is operating at the current time. Most of Kala Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kala Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kala Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kala Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |